A multinational pharmacoeconomic analysis of oral therapies for onychomycosis

Autor: Arikian, SR, Einarson, TR, Kobeltnguyen, G, Schubert, F, Allen, R, Baran, R, Bergman, W, Bitetto, L, Blattstein, JS, Breda, M, Clement, W, De Cuyper, C, Difonzo, E, Van Doorstaer, E, Doyle, JJ, Effendy, Isaak, Eichmann, A, Feuilhade, M, Figueiredo, A, Flori, YA, Germaine, GERMAINE, Camarasa, JMG, Ginter, G, Gisbert, R, Goodfield, M, Groeneweg, DA, Gunn, D, Hannuksela, M, Havu, V, Knappe, E, Koussidou- Eremonti, T, Lateur, N, Lee, RE, Lucioni, C, Mathioudaki, E, Mikultis, R, Nolting, S, Panagiotidou, D, Pekurinen, M, Pereira, J, Rey, JP, Pietrini, P, Soares, AP, Pirard, C, Roberts, DT, Rovira, J, Rufli, T, Rutten, F, Sommer, JH, Spangler, E, Stary, A, Stavrianeas, N, Stavropoulos, P, Stubb, S, Taddio, A, Topolewski, K, Tosti, A, Yfantopoulos, J, Vagena, A, Van Hecke, E, Vareltzidis, A, Zalinski, J
Rok vydání: 1994
Předmět:
Zdroj: British Journal of Dermatology. 130:35-44
ISSN: 1365-2133
0007-0963
DOI: 10.1111/j.1365-2133.1994.tb06093.x
Popis: Due to increased interest in economic evaluation and the rapid international spread of new healthcare technologies across borders, there is a need to interpret economic evaluations on a worldwide basis. We conducted a multinational cost-effectiveness analysis, from a government payer perspective, comparing four primary oral treatment regimens for onychomycosis of the fingernails and toenails: griseofulvin, itraconazole, ketoconazole and terbinafine. We used a four-step pharmacoeconomic research model which includes all relevant factors affecting costs in 13 countries: Austria, Belgium, Canada, Finland, France, Germany, Greece, Italy, The Netherlands, Portugal, Spain, Switzerland and the U.K. A worldwide meta-analysis of published clinical data served as the statistical input for the pharmacoeconomic model, and demonstrated that terbinafine had the highest success rates (95.0% and 78.3%) of the clinical comparators for fingernails and toenails, respectively. We found that terbinafine was the most effective therapy in relation to cost (therefore giving it the lowest cost-effectiveness ratio) for both infections in all health-care systems analysed.
Databáze: OpenAIRE
Externí odkaz: